Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The delivery of clinical care, research, and education in neuro-rehabilitation in Oxford will be revolutionised by an innovative partnership with Quinnipiac University, Hartford, USA.

Quinnipiac students Sean Pennetti and Evan Jameyfield

The Nuffield Department of Clinical Neurosciences (NDCN) at the University of Oxford, and the Oxford University Hospitals NHS Foundation Trust, are already known for basic and translational neuroscience research. But delivery of neuro-rehabilitation services is fragmented, which limits clinical care and research opportunities, especially for patients with progressive MS where the needs are greatest. Quinnipiac has a nationally respected neuro-rehabilitation programme, with a comprehensive clinical care model and access to a vast longitudinal clinical, biofluid, and imaging repository for research.

The aim is for Oxford to become a world-leading centre of excellence in restorative neuroscience.
- Associate Professor Gabriele De Luca

The partnership has been negotiated by Associate Professor Gabriele De Luca, Director of Clinical Neurosciences Undergraduate Education in the Medical Sciences Division at the University of Oxford. Together with senior leadership in NDCN, he has secured $3.6m for Phase One of the partnership. Contributions have been made by Quinnipiac University, Trinity Health New England, and Oxford University Hospitals NHS Foundation Trust.

 

This money will fund a five-year medical student exchange programme starting this July. The four medical school participants, who were selected through a competitive application process, are Sean Pennetti and Evan Jameyfield from Quinnipiac and Lucy Kirkwood and Matthew Williams from Oxford. In September, Sam Baskharoun and Vidhi Rao from Quinnipiac and James Towner and Hibatullah Abuelgasim of Oxford will take part in the programme.

Dr Robert Krug, the William and Barbara Weldon Chair and director of the Institute for Rehabilitation Medicine at the Netter School at Quinnipiac, will join Dr De Luca in leading the exchange programme.

‘This the first phase of a partnership that we hope will result in a long-term sustainable relationship between Quinnipiac, Oxford and Mount Sinai,’ said Krug, who also is president and executive medical director of Mount Sinai Rehabilitation Hospital. ‘Not only is this an incredible opportunity for medical students at the Netter School and the University of Oxford, but we believe both institutions will benefit from the collaboration.’

Future plans include the funding of two research fellowship posts. It is envisaged that Quinnipiac’s clinical team will provide rehabilitation expertise so that Oxford can create a comprehensive care centre for progressive MS that integrates clinical care, research, and education.

Similar stories

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Ensuring LGBTQI+ people are treated fairly in mental health data

Andrey Kormilitzin outlines a new participatory study aimed at improving AI to take account of LGBTQI+ people so that their needs are better met by mental health services.

Community play packs inspire families to be more playful at home

A project led by Alex Hendry working with Oxford Brookes has engaged with parents and early years practitioners in a bid to help families spend more time playing with their children.

Life and Mind Building construction tops out

Another milestone was reached this week with the topping out ceremony of the new Life and Mind Building.

Major trials to test effectiveness of cannabidiol on psychosis

Global study involving three clinical trials will investigate the effectiveness of cannabidiol (CBD) in treating people with psychosis or psychotic symptoms, thanks to a multi-million pound grant to Oxford University.